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Abstract Germ-line mutations of the breast cancer suscept-
ibility gene 1 (BRCA1) confer a high risk for breast and ovarian
cancer in women and prostate cancer in men. The BRCA1
protein contributes to cell proliferation, cell cycle regulation,
DNA repair and apoptosis ; however, the mechanisms underlying
these functions of BRCA1 remain largely unknown. Here, we
showed that, in Du-145 human prostate cancer cells, enhanced
expression of BRCA1 resulted in constitutive activation of signal
transducer and activator transcription factor 3 (STAT3) tyrosine
and serine phosphorylation. Moreover, Janus kinase 1 (JAK1)
and JAK2, the upstream activators of STAT3, were also
activated by BRCA1. Immunoprecipitation assay showed that
BRCA1 interacted with JAK1 and JAK2. Blocking STAT3
activation using antisense oligonucleotides significantly inhibited
cell proliferation and triggered apoptosis in Du-145 cells with
enhanced expression of BRCA1. These findings indicate that
BRCA1 interacts with the components of the JAK^STAT
signaling cascade and modulates its activation, which may
provide a new critical survival signal for the growth of breast,
ovarian and prostate cancers in the presence of normal
BRCA1. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Germ-line mutations of the breast cancer susceptibility gene
1 (BRCA1) on human chromosome 17q21 confer a high risk
for breast and ovarian cancers in women and prostate cancer
in men [1^5]. BRCA1 encodes a 1863 amino acid, 220 kDa
nuclear phosphoprotein containing a conserved amino-termi-
nal RING ¢nger domain and an acidic carboxyl-terminal
transcriptional activation domain [6,7]. The BRCA1 protein
acts as tumor suppressor and plays important roles in cell
proliferation, cycle regulation, DNA damage and repair, ge-
netic instability and various transcriptional pathways,
although its precise functions have not been elucidated (re-
viewed in [8^11]). Brca1 (3/3) mice with targeted deletion
of Brca1 developed normally and were fertile, but died by
embryo day 7.5, suggesting that Brca1 is essential for embry-
onic cell proliferation in mice [12]. Similar ¢ndings were re-
ported by other researchers, con¢rming the importance of
Brca1 in development [13,14]. Overexpression of BRCA1 in-
hibited cell growth and conferred increased susceptibility to
apoptosis caused by cytotoxic agents [15^17]. Our recent stud-
ies indicated that BRCA1 suppressed the transcriptional ac-
tivity of the estrogen receptor (ER-K), suggesting a role for
BRCA1 in regulating estrogen-stimulated mammary cell
growth and a speci¢c mechanism of hormone organ cancer
suppression [18]. Although it has been known that some
BRCA1 functions may be associated with its interaction
with cell regulatory genes and factors, such as cyclins, cy-
clin-dependent kinases, Rad51, c-Myc, RB, p53 and p53-tar-
geted genes and others, the mechanisms of these activities are
not well understood (reviewed in [8^11]).
The signal transducer and activator transcription factor
(STAT) signaling pathway can be activated by more than
35 cytokines and growth factors, and plays critical roles in a
wide variety of cellular functions in the hematopoietic, immu-
nologic, neuronal and hepatic systems (reviewed in [19^21]). It
is well established that the binding of a cytokine or growth
factor to its receptor activates the receptor-associated tyrosine
kinases, known as JAK1^3 and Tyk2, followed by activation
of STATs (reviewed in [19^21]). Tyrosine and serine phos-
phorylation of STATs are required for their transactivation
[22,23], nuclear translocation [24], DNA binding [25,26] and
dimerization [27]. In addition, many viral oncoproteins, in-
cluding v-Src, v-Abl, HTLV-1, v-Ros and v-Eyk, have been
shown to activate STATs [28^32]. Constitutively activated
STATs have been identi¢ed in many tumor cell lines and
primary tumors, including breast and prostate cancer [33^
36]. The essential role of constitutive activation of STAT3
in tumorigenesis is clearly demonstrated by the fact that over-
expression of constitutively activated STAT3 in 3Y1 cells
caused cell transformation and tumor formation [37]. Recent
studies have also shown that BRCA1 can interact with
STAT1 and regulate the transcription of a subset of interfer-
on-gamma (IFN-Q) target genes [38]. In this study, we inves-
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tigated whether BRCA1 a¡ects activation of STAT3, JAK1
and JAK2. We found that BRCA1 physically interacted with
JAKs followed by activation of STAT3 in Du-145 human
prostate cancer cells. Moreover, inactivation of STAT3 inhib-
ited cell proliferation and induced apoptosis in BRCA1-over-
expressing Du-145 cells.
2. Materials and methods
2.1. Cell culture and transfection
The Du-145 human prostate cell line was obtained from ATCC
(Rockville, MD, USA) and maintained in Dulbecco’s modi¢ed Eagle’s
medium (BioWhittaker, Walkersville, MD, USA) supplemented with
10% fetal calf serum, 2 mM glutamine, 100 Wg/ml streptomycin and
100 U/ml penicillin G. The establishment and characterization of sta-
bly transfected Du-145 cell clones with BRCA1 were described pre-
viously [17]. An expression vector encoding a wild-type (wt) BRCA1
cDNA was generated by inserting the corresponding polymerase chain
reaction (PCR)-generated full-length human BRCA1 cDNA into
pcDNA3 plasmid (HindIII^NotI sites) containing a neomycin-resistant
gene (kindly provided by M. Erdos, NIH, Bethesda, MD, USA). Du-
145 cells were transfected with wt BRCA1-pcDNA3 plasmid or con-
trol pcDNA3 plasmid using lipofectamine (Life Technologies) and
selected in medium containing 0.5 Wg/ml G-418. G-418-resistant clones
were isolated, expanded and screened by immunoblot assay and semi-
quantitative reverse transcription-PCR assay. Clones expressing the
highest expression of BRCA1 protein were chosen for further studies.
A tetracycline (TCN)-regulated BRCA1 expression system was devel-
oped using a Tet-O¡ system (Clontech), which has two components:
(1) a regulator plasmid pTet-O¡, which expresses a fusion of the Tet
repressor and VP16 activation domain of herpes simplex virus under
the control of the strong immediate early CMV promoter and (2) a
response plasmid pTRE, which contains the Tet-responsive element
(TRE) upstream of the minimal immediate early CMV promoter and
a multicloning site. Du-145 cell clones with transfection of TCN-in-
ducible BRCA1 plasmid were established by two separate stable trans-
fections, ¢rst plasmid pTet-O¡ and secondly plasmid pTRE with full-
length BRCA1 cDNA cloned into the pTRE vector (pTRE-BRCA1).
Tet-O¡/BRCA1 Du-145 cell clones with double transfections were
screened for BRCA1 expression induced by removal of TCN and
maintained in medium containing 2 ng/ml TCN.
2.2. Immunoprecipitation (IP) and immunoblot analysis
Total cell extracts were prepared in JAK lysis bu¡er (25 mM
HEPES, pH 7.5, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 1%
Nonidet P-40, 0.1% (v/v) 2-mercaptoethanol, 10 nM okadaic acid,
5 mM benzamidine, 0.5 mM sodium pyrophosphate, 0.5 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl £uoride (PMSF), 10
Wg/ml antipain, 10 Wg/ml aprotinin, 10 Wg/ml leupeptin). The concen-
tration of protein was determined with the Bradford reagent (Bio-
Rad). The extracts were subjected to IP for 16 h at 4‡C with anti-
bodies to BRCA1 (Ab1+Ab2+Ab3, Oncogene), JAK1 or JAK2 (Up-
state Biotechnology, Lake Placid, NY, USA). After the addition of
protein A/G agarose (Life Technologies, NY, USA), the reaction
mixtures were incubated for an additional 4 h. The immunoprecipi-
tates were extensively washed with JAK lysis bu¡er and subjected to
electrophoresis through sodium dodecyl sulfate (SDS)^polyacrylamide
gel. The separated proteins were then transferred to a nitrocellulose
membrane followed by immunoblot analysis.
Immunoblot analysis was described previously [39]. Cells were re-
suspended in lysis bu¡er (30 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
PMSF, 1 mM Na3VO4, 1% Nonidet P-40, 10% glycerol) and then
centrifuged for 10 min at 4‡C. Protein concentration was quantitated
using the Bradford reagent (Bio-Rad). An aliquot of 40 Wg of protein
was mixed with an equivalent volume of 2U protein loading bu¡er
containing L-mercaptoethanol and boiled for 5 min before loading
onto an SDS/8% polyacrylamide gel. STAT3, JAK1, JAK2 and
anti-phosphotyrosine antibodies were obtained from Upstate Biotech-
nology (Lake Placid, NY, USA). Anti-phospho-STAT3 antibodies
(Tyr705 and Ser727) were obtained from New England Bio-Lab. Pro-
tein bands were revealed by using an enhanced chemiluminescence
detection system (Amersham Life Science) as instructed by the man-
ufacturer.
2.3. DNA mobility gel shift assay (DMSA)
Activation of STAT3 DNA binding was determined by DMSA, as
described previously [40], using oligo m67 (a high a⁄nity serum in-
duce element m67) (5PGTG CAT TTC CCG TAA ATC TTG TCT
ACA3P).
2.4. JAK autophosphorylation assay
Exponentially growing cells were harvested, washed twice with
phosphate bu¡ered saline containing 1 mM Na3VO4, and lyzed in
0.5 ml of lysis bu¡er (30 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
phenylmethylsulfonyl £uoride, 1 mM Na3VO4, 1% Nonidet P-40, 10%
glycerol). Immunoprecipitated complexes were washed twice with lysis
bu¡er and once with kinase bu¡er (50 mM Tris, pH 7.4, 5 mM
MgCl2, 10 mM MnCl2, 0.1 mM Na3VO4). Pellets were resuspended
in 50 Wl of kinase bu¡er containing 5 WCi [Q-32P]ATP (Dupont, NEN)
and incubated at 30‡C for 10 min. Beads were washed twice with 500
Wl of stop bu¡er (50 mM Tris, pH 7.4, 150 mM NaCl, 10 mM
EDTA), and then boiled in SDS sample bu¡er containing 2.5% 2-mer-
captoethanol for 5 min. The solubilized proteins were resolved by
SDS^PAGE, followed by autoradiography.
2.5. [3H]Thymidine uptake
Following transfection of cells with STAT3 sense or antisense oli-
gonucleotides for 48 h, [3H]thymidine (2^5 WCi/ml) was added to the
culture for 2 h. Cells were then dissolved by the addition of 1.0 ml of
0.5 N NaOH, collected, mixed with 1.5 ml of H2O, and precipitated
with 0.5 ml of 50% trichloroacetic acid (TCA). The precipitate was
collected on glass ¢lters, washed twice with 5% TCA, and the retained
radioactivity determined by liquid scintillation spectrometry. Each
time point for each set of experiment was determined in triplicate.
2.6. Apoptosis assay
Cell apoptosis was measured by 3P-end labeling DNA with terminal
deoxynucleotidyl transferase (Life Technologies) as described previ-
ously [41]. Brie£y, genomic DNA was isolated and subjected to label-
ing reaction, which was performed in a ¢nal volume of 50 Wl, con-
taining 31 Wl DNA, 10 Wl 5Ureaction bu¡er (1 M potassium
cacodylate, 0.125 M Tris^HCl, 1.25 mg/ml bovine serum albumin;
pH 6.6), 5 Wl CoCl2, 5 Wl [K32P]ddATP (17 pmol; 50 WCi), and 1 Wl
(25 U) terminal transferase enzyme. The reaction is allowed to pro-
ceed for 60 min at 37‡C, and terminated by addition of 5 Wl 0.25 M
EDTA (pH 8.0). Labeled DNA is separated from unincorporated
radionucleotide by using Chroma spin column (Clontech, Palo Alto,
CA, USA). The labeled sample is loaded onto a 2% agarose gel and
separated by electrophoresis. The gel is then dried and exposed to X-
ray ¢lm. The amount of radiolabeled ddATP incorporated into the
high (s 20 kb) and low (6 20 kb) molecular weight DNA fractions
can be quantitated by cutting the respective fraction of DNA from the
dried gel and counting for 1 min in a L-counter.
3. Results and discussion
To investigate whether BRCA1 interacts with STAT3, we
¢rst compared the expression of BRCA1 protein in Du-145
human prostate cancer cells : parental, control pcDNA3 vec-
tor transfected (Neo) clones and wt BRCA1 transfected
(wtBRCA1) clones. Parental Du-145 cells contain a low basal
level of endogenous BRCA1 and stable transfection of full-
length BRCA1 cDNA signi¢cantly increased the BRCA1 pro-
tein expression (Fig. 1a). Establishment and characterization
of the transfection clones have been previously described in
detail [17]. Du-145 clones transfected with wtBRCA1 exhib-
ited only a slight decrease in growth rate (average doubling
time = 22 h), as compared with Du-145 parental cells and the
control Neo vector transfected clones (average doubling
time = 25 h). As a set of representative results shown in Fig.
1a, enhanced expression of BRCA1 resulted in the constitutive
activation of STAT3 binding in all wtBRCA1 clones com-
pared to Neo clones. To further de¢ne the molecular mecha-
nism by which enhanced expression of BRCA1 activates
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STAT3, wtBRCA1 clone 2 (BRCA1^2) was chosen for further
experiment. As shown in Fig. 1b, signi¢cant tyrosine (Tyr705)
and serine (Ser727) phosphorylation of STAT3 were observed
in BRCA1^2 clone but not in parental or Neo clones, while
the levels of STAT3 protein expression were una¡ected in all
three group cells.
The constitutive activation of STAT3 in Du-145 clones
over-expressed with wtBRCA1 may have occurred during
Fig. 1. Constitutively active JAK^STAT3 in Du-145 human prostate cancer cells containing overexpression of BRCA1. Clones were established
and characterized in Du-145 cells stably transfected with control pcDNA3 vector containing neomycin resistance gene (Neo) or full-length
wtBRCA1 cDNA (BRCA1) as described previously [17]. a: Exponentially growing Du-145 parental cells, two pcDNA3 vector transfected
clones and four wtBRCA1 clones were harvested for immunoblot analysis using BRCA1 antibody (C-20, Santa Cruz Biotechnology, CA, USA)
or DMSA using m67 oligo as a probe. b: Exponentially growing parental Du-145 cells, Neo-2 clone and BRCA1^2 clone were harvested for
Western blotting. c: Du-145 cells were stably transfected with an inducible BRCA1 in TCN-o¡ vector as described in Section 2. BRCA1 trans-
fected Du-145 cells were grown in the growth media in the presence (+Tet) or the absence (3Tet) of TCN (2 ng/ml) for the indicated time. To-
tal cell extracts were prepared and subjected to immunoblot analysis with anti-BRCA1, anti-STAT3, and anti-phospho-STAT3 (Tyr705). d and
e: Total cell extracts were prepared from parental Du-145 cells, Neo-2 clone and BRCA1^2 clone, respectively, and subjected to IP with anti-
bodies to JAK1 or JAK2. The resulting immunoprecipitates were then subjected to immunoblot analysis with anti-phosphotyrosine antibodies
(d), or subjected to in vitro autophosphorylation assay (e). The radioactivities on the blots were quanti¢ed by phosphorimaging. Values shown
are means þ S.E.M. from three independent experiments, expressed as fold changes over parental control.
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the process of clonal selection. To distinguish changes that
occur within days from those occurring more slowly, we es-
tablished clones with TCN-regulated wtBRCA1 expression as
described in Section 2. As a set of representative results shown
in Fig. 1c, in Tet-O¡/wtBRCA1 clone 9 (Tet-O¡/wtBRCA1-
9), removal of TCN (3TCN) from the culture medium mark-
edly increased expression of BRCA1 protein and activated the
tyrosine (Tyr705) phosphorylation of STAT3, while it did not
a¡ect STAT3 protein expression. Similar results were ob-
tained in other Tet-O¡/wtBRCA1 clones (data not shown).
These observations, consistent with the assays of stably trans-
fected Du-145 clones shown in Fig. 1a,b, suggest that BRCA1
does constitutively activate STAT3. Interestingly, other
STATs, such as STAT1 and STAT5 were not activated in
either transiently or stably transfected Du-145 cells with
wtBRCA1 (data not shown).
We next determined whether the constitutive activation of
STAT3 in wtBRCA1-overexpressing Du-145 cells is triggered
by activation of STAT3 upstream activators, JAK1 and
JAK2, by BRCA1. The activation of JAK1 and JAK2 was
determined using either IP-immunoblot assay (Fig. 1d) or ki-
nase assay (Fig. 1e). As shown in Fig. 1d, signi¢cant tyrosine
phosphorylation of JAK1 or JAK2 protein was observed in
the immunoprecipitates from wtBRCA1 clones compared to
Du-145 parental cells and control Neo clones. JAK1 and
JAK2 activities were also markedly increased in BRCA1
clones as demonstrated by an in vitro kinase assay (Fig. 1e).
These ¢ndings indicate that the constitutive activation of
STAT3 may result from the BRCA1 activation of JAK1
and JAK2.
To determine whether BRCA1 activation of JAK1 and
JAK2 is due to direct physical interaction of BRCA1 with
JAKs, an IP assay was performed. Cell extracts from control
Neo clones or BRCA1 transfected clones were immunopreci-
pitated by using BRCA1, JAK1 or JAK2 antibody and fol-
lowed by immunoblot analysis with JAK1, JAK2 or BRCA1.
As a set of representative results shown in Fig. 2, both JAK1
and JAK2 proteins were detected in BRCA1 immunopre-
cipitation of BRCA1 transfected clone (BRCA1^2), but not
of the control Neo clone (Neo-2). Under the same condition,
STAT3 and gp130 were not co-precipitated with BRCA1
(data not shown). BRCA1 protein was also detectable in
JAK1 and JAK2 immunoprecipitation. These ¢ndings indi-
cate that BRCA1 is physically associated with JAK1 and
JAK2.
Interleukin-6 (IL-6) has been found to activate STAT3 in
prostate cancer cells [42,43], we thus determined whether the
constitutive activation of STAT3 in wtBRCA1 clones is af-
fected by IL-6 stimulation. Control Neo clones and BRCA1
transfected clones were exposed to IL-6 in the presence of or
in the absence of IL-6 antibody and then subjected to immu-
noblot analysis. As a set of representative results are shown in
Fig. 3a, IL-6 signi¢cantly activated tyrosine (Tyr705) phos-
phorylation of STAT3 in parental Du-145 cells and Neo
clones, and slightly increased tyrosine phosphorylation of
STAT3 in wtBRCA1 Du-145 clones as well. Neutralizing anti-
body to IL-6 abrogated the IL-6-activated tyrosine phosphor-
ylation of STAT3 in parental Du-145 cells or Neo clones, but
did not cause any in£uence on the constitutive activation of
STAT3 in wtBRCA1 clones (Fig. 3b). The level of the IL-6
gene expression was similar in Neo clones and in BRCA1
transfected clones (data not shown). These ¢ndings suggest
that the constitutive STAT3 activation in wtBRCA1 Du-145
clones is not due to IL-6 stimulation.
It has been shown that BRCA1 inhibited or delayed growth
of breast and ovarian cancer cells and enhanced apoptosis
induction in response to cytotoxic agents, including anti-can-
cer agents [8^11]. As described previously [17], overexpression
of BRCA1 only caused a slightly decrease in the proliferation
rate of Du-145 cells (average doubling time = 25 h for Neo
clones and 22 h for BRCA1 clones). However, BRCA1 sig-
ni¢cantly increased apoptosis induction after DNA damage
caused by anti-cancer agents. Since constitutively active
STAT3 has been shown to play a critical role in cell trans-
formation and tumor formation [37], we, therefore, deter-
mined whether constitutively active STAT3 exerts any e¡ects
on the proliferation and apoptosis of Du-145 cells in the pres-
ence of wtBRCA1. As shown in Fig. 4, blocking STAT3 ex-
pression using STAT3 antisense oligonucleotides signi¢cantly
inhibited cell proliferation and induced apoptosis in BRCA1
clones but not in Neo clones, while sense STAT3 oligonucleo-
tides did not signi¢cantly a¡ect the proliferation or apoptosis
in both Neo- and BRCA1 clones. These ¢ndings indicate that
the constitutive activation of STAT3 by BRCA1 is a survival
signal for escaping the tumor suppressing activity of BRCA1.
Although all the results described above are obtained from
one clone (Neo-2, wtBRCA1^2, Tet-O¡/wtBRCA1-9), similar
¢ndings were also observed in several other transfected clones.
Taken together, we demonstrate for the ¢rst time that
BRCA1 associates with JAK1 and JAK2 in vivo, and consti-
tutively activated the JAK^STAT3 signaling pathway in Du-
145 cells. Abrogation of STAT3 activation markedly inhibited
cell proliferation and induced apoptosis in wtBRCA1 cells
compared to control Neo cells. Therefore, these novel ¢ndings
Fig. 2. Co-precipitation of BRCA1 with JAK1 and JAK2. Total
cell extracts were prepared from control Neo-2 clone and BRCA1^2
clone in JAK lysis bu¡er and subjected to IP with antibodies to
BRCA1. The resulting immunoprecipitates were subjected to immu-
noblot analysis with antibodies to JAK1 or JAK2 as indicated.
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suggest that BRCA1 promotes cell survival signal via activat-
ing the JAK^STAT3 signal pathway, which may provide a
new mechanism for the growth of breast, ovarian and prostate
cancers in the presence of normal BRCA1, since 90% sporadic
breast cancers express normal BRCA1 [8^11]. Indeed, several
breast cancer cell lines and primary breast tumors express
constitutively active STAT3 [33^36], which has been proposed
as a target for tumor therapy [33]. Our unpublished data
showed that several prostate cancer cell lines also expressed
constitutively active STAT3. Whether endogenous BRCA1 is
responsible for the constitutive activation of STAT3 in these
cells remains unknown. We have tried to examine whether
suppression of BRCA1 gene expression attenuated constitu-
tive STAT3 activation in these cells. However, unfortunately,
we failed to knock out BRCA1 gene expression by either using
antisense oligonucleotides or over-expressing BRCA1 anti-
sense mRNA in prostate cancer cells, this is probably due
to the fact that BRCA1 mRNA is very large and may contain
Fig. 4. Constitutively active STAT3 mediates the proliferative and survival signals in BRCA transfected cells. wtBRCA1 or control pcDNA3
vector (neo) transfected Du-145 cells were transfected with sense STAT3 (5PCCATTGGGCCATCCTGTTTCT3P) or antisense STAT3 (5PA-
GAAACAGGATGGCCCAATGG3P). After 48 h, cells were subjected to proliferation or apoptosis assay. Proliferation assay was conducted by
[3H]thymidine incorporation into DNA. Apoptosis was conducted by measuring DNA fragmentation as described Section 2. Values shown in
the panel are means þ S.E.M. from three di¡erent experiments, expressed as fold changes over corresponding control. Signi¢cant di¡erence
from corresponding control is indicated by asterisks: *P6 0.01.
Fig. 3. Constitutively active STAT3 is not due to IL-6 stimulation. a: Parental Du-145 cells, control Neo-2 clone, or BRCA1^2 clone were ex-
posed to IL-6 (20 ng/ml) for 30 min, total cell extracts were then subjected to immunoblot analysis with antibodies to STAT3 tyrosine phos-
phorylation (Tyr705) or STAT3. b: Parental Du-145 cells and control Neo-2 clone were exposed to IL-6 (20 ng/ml) for 8 h in the presence or
in the absence of anti-IL-6 antibody. BRCA1 transfected cells were incubated directly with anti-IL-6 antibody for 24 h. Total cell extracts were
then subjected to immunoblot analysis with antibodies to STAT3 tyrosine phosphorylation (Tyr705) or STAT3.
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a secondary structure. Further experiments are required to
demonstrate whether endogenous BRCA1 is responsible for
STAT3 activation in breast and prostate cancer cells. If en-
dogenous BRCA1 was able to constitutively activate STAT3,
the next obvious question is why normal breast and ovarian
tissues that express normal BRCA1 do not contain active
STAT3. The reason for this is not clear. One possibility is
that the tumor cells express an adapter protein(s), which is
required for BRCA1-mediated STAT3 activation but does not
express in normal tissue cells.
It has been shown that the JAK^STAT signaling pathway
can be activated by more than 35 cytokines and growth fac-
tors, and this activation is transient [19^21]. Recently, Ouchi
et al. [38] reported that BRCA1 is able to bind to the STAT1
transcriptional activation domain and is required for induc-
tion of a subset of IFN-Q target genes. Although the possible
contribution of other cytokines or growth factors to BRCA1
activation of JAK^STAT3 cannot be ruled out, two lines of
evidence suggest that IL-6 stimulation may not be involved.
First, we found that IL-6 monoclonal antibody can abrogate
IL-6-activated STAT3, but failed to block wtBRCA1-acti-
vated STAT3 in Du-145 cells. Second, the IL-6 gene expres-
sion was the same in Neo and BRCA1 clones (unpublished
data). In addition to the cytokines and growth factors, many
viral oncoproteins have been shown to activate STATs, in-
cluding v-Src [28], v-Abl [29], HTLV-1 [30], v-Ros [31] and
v-Eyk [32]. Whether these oncoproteins are involved in
BRCA1-mediated STAT3 activation requires further investi-
gation.
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